ArriVent BioPharma Inc. C... (AVBP)
NASDAQ: AVBP
· Real-Time Price · USD
19.54
0.92 (4.94%)
At close: Aug 15, 2025, 3:59 PM
19.58
0.20%
After-hours: Aug 15, 2025, 05:41 PM EDT
ArriVent BioPharma Common Stock Income Statement
Financials in USD. Fiscal
year is
undefined.
| Fiscal Year | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 |
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Income | -148.33M | -140.41M | -94.31M | -93.72M | -86.2M | -83.09M | -74.59M | -61.91M | -56.97M | -41.73M | -36.91M | -26.46M | -14.7M | -7.35M |
Interest Income | 11.35M | 12.95M | 13.82M | 12.67M | 11.32M | 8.51M | 5.26M | 3.33M | 1.02M | n/a | n/a | n/a | n/a | n/a |
Pretax Income | -136.98M | -127.46M | -80.49M | -81.05M | -74.89M | -74.58M | -69.33M | -58.58M | -55.95M | -41.73M | -36.91M | -26.46M | -14.7M | -7.35M |
Net Income | -136.98M | -127.46M | -80.49M | -81.05M | -74.89M | -74.58M | -69.33M | -58.58M | -55.95M | -41.73M | -36.91M | -26.46M | -14.7M | -7.35M |
Selling & General & Admin | 19.07M | 17.09M | 15.3M | 14.87M | 13.16M | 11.47M | 9.71M | 8.39M | 7.64M | 6.91M | 6.47M | 4.68M | 3M | 1.5M |
Research & Development | 129.26M | 123.32M | 79M | 78.85M | 73.04M | 71.62M | 64.88M | 53.52M | 49.33M | 34.82M | 30.43M | 21.79M | 11.7M | 5.85M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 148.33M | 140.41M | 94.31M | 93.72M | 86.2M | 83.09M | 74.59M | 61.91M | 56.97M | 41.73M | 36.91M | 26.46M | 14.7M | 7.35M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 148.33M | 140.41M | 94.31M | 93.72M | 86.2M | 83.09M | 74.59M | 61.91M | 56.97M | 41.73M | 36.91M | 26.46M | 14.7M | 7.35M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 35.01M | 33.9M | 33.58M | 33.58M | 33.51M | 33.49M | 33.49M | 33.49M | 33.49M | 33.49M | 33.49M | 33.49M | 1.28M | 1.28M |
Shares Outstanding (Diluted) | 35.01M | 33.9M | 33.58M | 33.58M | 33.51M | 33.49M | 33.49M | 33.49M | 33.49M | 33.49M | 33.49M | 33.49M | 1.28M | 1.28M |
EPS (Basic) | -4.02 | -3.77 | -2.39 | -2.41 | -2.23 | -2.22 | -2.06 | -1.74 | -1.66 | -6.78 | -12.18 | -11.87 | -11.52 | -5.76 |
EPS (Diluted) | -4.02 | -3.77 | -2.39 | -2.41 | -2.23 | -2.22 | -2.06 | -1.74 | -1.66 | -6.78 | -12.18 | -11.87 | -11.52 | -5.76 |
EBITDA | -146.11M | -140.41M | -94.31M | -93.72M | -86.2M | -83.09M | -74.59M | -61.91M | -56.97M | -34.38M | -22.21M | -11.77M | n/a | n/a |
EBIT | -146.11M | -140.41M | -94.31M | -93.72M | -86.2M | -83.09M | -74.59M | -61.91M | -56.97M | -41.73M | -36.91M | -26.46M | -14.7M | -7.35M |
Depreciation & Amortization | n/a | n/a | n/a | n/a | n/a | n/a | 12.17M | 22.61M | 34.38M | 41.73M | 36.91M | 26.46M | 14.7M | 7.35M |